Throughout the last decade, more and more companies have popped up that are focused on discovering and developing psychedelic compounds to revolutionize the treatment of mental illness. A number of these companies, including Atai Life Sciences (NASDAQ:ATAI) and Compass Pathways (NASDAQ:CMPS) are already publicly traded.
But today we will take a closer look at some of the psychedelic-focused companies that are private, specifically those that have raised the most money. The information below was compiled from Psilocybin Alpha.
Beckley Psytech
Beckley Psytech is a private company utilizing multiple different psychedelics compounds to address a myriad of mental health issues, according to Psilocybin Alpha.
The founders of Beckley Psytech bring valuable experience in the space from running the Beckley Foundation, a non-profit focused on furthering the psychedelic space founded in 1998.
“We collaborate with leading scientific and political institutions worldwide to design and develop ground-breaking research and global policy initiatives,” according to the foundation’s website.
In August 2021, Beckley announced it raised around $80 million in a Series B financing round.
Visit Beckley Psytech’s website to learn more.
Delix Therapeutics
Delix Therapeutics is a company specializing in “psychoplastogens,” novel neuroplasticity-promoting therapeutics. Delix hopes these psychoplastogens will have strong efficacy while providing a safe alternative to other drugs in the space.
Delix's compounds are small molecules that can effectively target the desired areas of the brain.
In September 2021, Delix announced it closed a $70 million Series A financing round.
Visit Delix’s website to learn more.
Gilgamesh Pharmaceutical
Gilgamesh is a private, pre-clinical biotech company focused on developing new chemical entities (NCEs) in the psychedelic space. Gilgamesh has an AI-powered drug development program, ENKIDU, named after the character in the “Epic of Gilgamesh” ancient tale
So far, Gilgamesh has four drugs in its pipeline, with three focused on alleviating the effects of depression, and the fourth in helping patients beat opioid addiction.
In May 2021, Gilgamesh announced the closing of its Series A financing round, raising $27 million.
Visit Gilgamesh Pharmaceutical’s website to learn more.
Editor's note: A previous version of this story did not properly cite Psilocybin Alpha.
